Albuterol Sulfate Solution
FDA Label NDC 0487-0301

32 label sections · Submitted to the FDA by Nephron Pharmaceuticals Corporation · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Nephron Pharmaceuticals Corporation for the product Albuterol Sulfate (NDC 0487-0301). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding other, description, clinical pharmacology, pharmacokinetics, animal pharmacology & or toxicology, clinical studies, indications and usage, contraindications, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Clinical Pharmacology

The prime action of beta-adrenergic drugs is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',-5'-adenosine monophosphate (cyclic AMP) from adenosine triphosphate (ATP). The cyclic AMP thus formed mediates the cellular responses. In vitro studies and in vivo pharmacologic studies have demonstrated that albuterol has a preferential effect on beta 2-adrenergic receptors compared with isoproterenol. While it is recognized that beta 2 -adrenergic receptors are the predominant receptors in bronchial smooth muscle, recent data indicate that 10% to 50% of the beta-receptors in the human heart may be beta 2-receptors. The precise function of these receptors, however, is not yet established. Controlled clinical studies and other clinical experience have shown that inhaled albuterol, like other beta-adrenergic agonist drugs, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes. Albuterol is longer acting than isoproterenol in most patients by any route of administration because it is not a substrate for the cellular uptake processes for catecholamines nor for catechol- O-methyl transferase.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because of the potential for tumorigenicity shown for albuterol in some animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Adverse Reactions

Clinical Trial Experience: Adverse events reported in >1% of patients receiving albuterol sulfate and more frequently than in patients receiving placebo in a four-week double-blind study are listed in the following table.

Table 1: Adverse Events with an Incidence of >1% of Patients Receiving Albuterol Inhalation Solution and Greater than Placebo (expressed as % of treatment group)
1.25 mg

(0.042%)

Albuterol Inhalation Solution

(n = 115)
0.63 mg

(0.021%)

Albuterol Inhalation Solution

(n = 117)


Placebo

(n = 117)
Asthma Exacerbation1311.18.5
Otitis Media4.30.90
Allergic Reaction0.93.41.7
Gastroenteritis0.93.40.9
Cold Symptoms03.41.7
Flu Syndrome2.62.61.7
Lymphadenopathy2.60.91.7
Skin/Appendage Infection1.700
Urticaria1.70.90
Migraine0.91.70
Chest Pain0.91.70
Bronchitis0.91.70.9
Nausea1.70.90.9

There was one case of ST segment depression in the 1.25 mg (0.042%) albuterol inhalation solution treatment group.

No clinically relevant laboratory abnormalities related to albuterol inhalation solution administration were seen in this study.

Postmarketing Experience: Metabolic acidosis has been reported after the use of albuterol inhalation solution. Because this reaction is reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate its frequency or establish a causal relationship to drug exposure.

Instructions For Use

  • Remove the vial from the foil pouch.
  • Twist the cap completely off the vial and squeeze the contents into the nebulizer reservoir (Figure 1).
    F:\daisy Assignment\6月份\06.20\albuterol-sulfate-inhalation-solution-6-20-2008\figure-04.jpg (F269bd00 Figure 04)

    F:\daisy Assignment\6月份\06.20\albuterol-sulfate-inhalation-solution-6-20-2008\figure-04.jpg (F269bd00 Figure 04)

  • Connect the nebulizer to the mouthpiece or face mask (Figure 2).
    F:\daisy Assignment\6月份\06.20\albuterol-sulfate-inhalation-solution-6-20-2008\figure-05.jpg (F269bd00 Figure 05)

    F:\daisy Assignment\6月份\06.20\albuterol-sulfate-inhalation-solution-6-20-2008\figure-05.jpg (F269bd00 Figure 05)

  • Connect the nebulizer to the compressor
  • Sit in a comfortable, upright position; place the mouthpiece in your mouth (Figure 3) or put on the face mask (Figure 4); and turn on the compressor.
  • ​

    F:\daisy Assignment\6月份\06.20\albuterol-sulfate-inhalation-solution-6-20-2008\figure-06.jpg (F269bd00 Figure 06)

    F:\daisy Assignment\6月份\06.20\albuterol-sulfate-inhalation-solution-6-20-2008\figure-06.jpg (F269bd00 Figure 06)

    Figure 4 (F269bd00 Figure 07)

    Figure 4 (F269bd00 Figure 07)

    • Breathe as calmly, deeply and evenly as possible through your mouth until no more mist is formed in the nebulizer chamber (about 5 - 15 minutes). At this point, the treatment is finished.
    • Clean the nebulizer (see manufacturer's instructions).
    • Note: Use only as directed by your physician. More frequent administration or higher doses are not recommended.

* Please review the disclaimer below.